Skip to the answer

Eltrombopag

Eltrombopag is a platelet-boosting medicine (a thrombopoietin receptor agonist) used for low platelet counts from immune thrombocytopenia (ITP) or chronic hepatitis C, and for severe aplastic anemia.

Brand names PromactaAlvaizEltrombopag Olamine
Drug class Thrombopoietin Receptor Agonist
Rx Forms 2
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026 Content updated Oct 2, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 16 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

✓No current FDA shortage listed · checked Oct 7, 2026
Eltrombopag at a glance The quick version — the full detail is in the Patient Information Guide below.
Dr. Brian Staiger, PharmD, BCPS
The Pharmacist’s Take By · Clinical pharmacist · Written

Eltrombopag (Promacta, Alvaiz) is a specialist medicine that raises low platelet counts by mimicking thrombopoietin, the body's natural platelet-growth signal. It is used for immune thrombocytopenia (ITP) after other treatments fall short, for low platelets from chronic hepatitis C, and for severe aplastic anemia, and it has been around since about 2008 and is available generically. It is usually fairly well tolerated, with nausea, diarrhea, headache and tiredness the complaints people notice most. The one thing to watch is its boxed warning for serious, even life-threatening liver damage (and worsening liver function in hepatitis C when paired with interferon and ribavirin), so regular liver blood tests are essential.

Clinical pearls

  • Keep it at least 2 hours before or 4 hours after dairy, antacids and mineral supplements like iron, calcium or zinc.
  • If you take a statin, especially rosuvastatin, your prescriber may lower its dose because eltrombopag can push statin levels up.
  • Tell the lab you take eltrombopag, since it can interfere with some bilirubin and creatinine test results.
  • Get an eye exam before starting and report any vision changes, because cataracts can develop or worsen on eltrombopag.
How we write & review this content — our editorial policy →
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾

Eltrombopag can cause serious, even life-threatening liver damage. If you have chronic hepatitis C and take it with interferon and ribavirin, it may also raise the risk of your liver function worsening (hepatic decompensation).

Your doctor will check liver blood tests before you start and regularly during treatment. Watch for yellow skin or eyes, dark urine, belly swelling, or confusion, and call your doctor right away if they appear.

Read the full warning on DailyMed →
How you get itPrescription only
Comes asTablet, Oral suspension
Earliest FDA record2008
Companies listing it with the FDA14
FDA label last updatedJan 30, 2026
FDA’s strongest warning (boxed)Yes, read the warning

Patient information guide A plain-language walkthrough of Eltrombopag, written from its FDA label.

What Eltrombopag is used for

▾

Eltrombopag treats low platelet counts and a bone marrow failure condition. Uses by product:

  • Persistent or chronic ITP: eltrombopag tablets, eltrombopag for oral suspension, and Promacta are used in patients 1 year and older who did not respond enough to corticosteroids, immunoglobulins, or splenectomy. Alvaiz is used in patients 6 years and older.
  • Chronic hepatitis C: treats low platelets so interferon-based therapy can start and continue. Alvaiz is for adults.
  • Severe aplastic anemia, first-line: eltrombopag tablets and Promacta, with standard immunosuppressive therapy, in patients 2 years and older.
  • Severe aplastic anemia, after insufficient response to immunosuppressive therapy: eltrombopag tablets, eltrombopag for oral suspension, and Promacta. Alvaiz is for adults.

It is not for myelodysplastic syndrome (MDS).

How Eltrombopag works

▾

Eltrombopag is a thrombopoietin (TPO) receptor agonist. It binds the TPO receptor (cMpl) and starts signals that make platelet-producing cells multiply and mature. That leads to more platelets.

Eltrombopag dosage

▾

Eltrombopag is taken by mouth, usually once daily, as tablets or an oral suspension depending on the product.

  • Take it on an empty stomach or with a low-calcium meal.
  • Separate it from antacids, dairy, and mineral supplements by 2 hours before or 4 hours after.
  • Your prescriber adjusts the amount based on platelet counts and other factors.
  • Alvaiz cannot be swapped milligram-for-milligram with other eltrombopag products.

Dosing details from the FDA-approved label

From the Eltrombopag prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.

  • Persistent or Chronic ITP (adult and pediatric patients 6 years and older)
    • 50 mg orally once daily
    • 25 mg orally once daily for patients of East-/Southeast-Asian ancestry or with mild, moderate, or severe hepatic impairment (Child-Pugh class A, B, C)
    • Consider 12.5 mg orally once daily for patients of East-/Southeast-Asian ancestry with hepatic impairment
    • Maximum: Do not exceed 75 mg per day
    • Adjust to maintain platelet count greater than or equal to 50 x 10^9/L; take without a meal or with a meal low in calcium (≤ 50 mg)
  • Persistent or Chronic ITP (pediatric patients aged 1 to 5 years)
    • 25 mg orally once daily
    • Maximum: Do not exceed 75 mg per day
    • Adjust to maintain platelet count greater than or equal to 50 x 10^9/L
  • Chronic Hepatitis C-associated Thrombocytopenia
    • Initiate at 25 mg orally once daily for all patients
    • Adjust to achieve target platelet count required to initiate antiviral therapy
    • Maximum: Do not exceed a daily dose of 100 mg
  • First-line Severe Aplastic Anemia
    • Orally once daily at 2.5 mg/kg (pediatric patients aged 2 to 5 years), 75 mg (pediatric patients aged 6 to 11 years) or 150 mg (patients aged 12 years and older) concurrently with standard immunosuppressive therapy
    • Reduce initial dose in patients of East-/Southeast-Asian ancestry; modify dosage for toxicity or elevated platelet counts
  • Refractory Severe Aplastic Anemia
    • Initiate at 50 mg orally once daily
    • Maximum: Do not exceed 150 mg per day
    • Reduce initial dose in patients with hepatic impairment or of East-/Southeast-Asian ancestry; adjust to maintain platelet count greater than 50 x 10^9/L
  • Alvaiz - Persistent or Chronic ITP (adult and pediatric patients 6 years and older)
    • 36 mg orally once daily
    • 18 mg orally once daily for patients of East-/Southeast-Asian ancestry or with mild to severe hepatic impairment
    • Maximum: Do not exceed 54 mg per day
    • Alvaiz is not substitutable with other eltrombopag products on a milligram per milligram basis
  • Alvaiz - Chronic Hepatitis C-associated Thrombocytopenia
    • Initiate at 18 mg orally once daily for all patients
    • Adjust to achieve target platelet count required to initiate antiviral therapy
    • Maximum: Do not exceed a daily dose of 72 mg
    • Not substitutable with other eltrombopag products on a milligram per milligram basis
  • Alvaiz - Refractory Severe Aplastic Anemia
    • Initiate at 36 mg orally once daily
    • Maximum: Do not exceed 108 mg per day
    • Reduce initial dose in patients with hepatic impairment or of East-/Southeast-Asian ancestry
Read the label’s full dosing text

2 DOSAGE AND ADMINISTRATION Take eltrombopag tablets without a meal or with a meal low in calcium (≤ 50 mg). Take eltrombopag tablets at least 2 hours before or 4 hours after any medications or products containing polyvalent cations, such as antacids, calcium-rich foods, and mineral supplements. (2.4, 7.1, 12.3) Persistent or Chronic ITP:Initiate eltrombopag tablets at 50 mg orally once daily for most adult and pediatric patients 6 years and older, and at 25 mg orally once daily for pediatric patients aged 1 to 5 years. Dose reductions are needed for patients with hepatic impairment and some patients of East-/Southeast-Asian ancestry. Adjust to maintain platelet count greater than or equal to 50 x 10 9/L. Do not exceed 75 mg per day. (2.1, 8.6, 8.7) Chronic Hepatitis C-associated Thrombocytopenia:Initiate eltrombopag tablets at 25 mg orally once daily for all patients. Adjust to achieve target platelet count required to initiate antiviral therapy. Do not exceed a daily dose of 100 mg. (2.2) First-line Severe Aplastic Anemia:Initiate eltrombopag tablets orally once daily at 2.5 mg/kg (in pediatric patients aged 2 to 5 years old), 75 mg (pediatric patients aged 6 to 11 years old), or 150 mg for patients aged 12 years and older concurrently with standard immunosuppressive therapy. Reduce initial dose in patients of East-/Southeast-Asian ancestry. Modify dosage for toxicity or elevated platelet counts. (2.3, 8.7) Refractory Severe Aplastic Anemia:Initiate eltrombopag tablets orally at 50 mg once daily. Reduce initial dose in patients with hepatic impairment or patients of East-/Southeast-Asian ancestry. Adjust to maintain platelet count greater than 50 x 10 9/L. Do not exceed 150 mg per day. (2.3, 8.6, 8.7) 2.1 Persistent or Chronic Immune Thrombocytopenia Use the lowest dose of eltrombopag tablets to achieve and maintain a platelet count greater than or equal to 50 x 10 9 /L as necessary to reduce the risk for bleeding. Dose adjustments are based upon the platelet count response. Do not use eltrombopag tablets to normalize platelet counts [see Warnings and Precautions (5.4)]. In clinical trials, platelet counts generally increased within 1 to 2 weeks after starting eltrombopag tablets and decreased within 1 to 2 weeks after discontinuing eltrombopag tablets [see Clinical Studies (14.1)] .

Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →

Eltrombopag side effects

▾

Common side effects vary by condition and include:

Common side effects

  • Nausea
  • Diarrhea
  • Headache
  • Fatigue
  • Fever
  • Cough
  • Anemia (low red blood cells)
  • Raised liver blood tests (ALT/AST)
  • Cough and upper respiratory infections

When to get medical help

  • Yellowing of your skin or eyes, dark urine, or severe belly pain: these can signal liver injury.
  • Swelling or fluid in the belly or confusion, especially if you have hepatitis C: these can signal liver decompensation.
  • Belly pain with nausea, vomiting, or diarrhea: this can signal a blood clot in a liver vein (portal vein thrombosis).
  • Signs of a blood clot, such as sudden leg swelling or pain, chest pain, or shortness of breath.
  • Changes in vision, since cataracts can develop or worsen.
  • Unusual bleeding or bruising.

Eltrombopag warnings and precautions

▾
  • Liver damage (boxed warning): can be severe and life-threatening. Liver tests are checked before and during treatment.
  • Hepatitis C: with interferon and ribavirin, risk of liver decompensation rises, especially with low albumin or higher MELD scores.
  • Blood clots: including portal vein clots in chronic liver disease. Do not aim to normalize platelet counts.
  • MDS: higher risk of death and progression to acute myeloid leukemia in a trial.
  • Cataracts: eye exams before and during treatment.
  • Lab test interference: eltrombopag can distort bilirubin and creatinine results.

Eltrombopag interactions

▾

These can change how eltrombopag or other medicines work:

  • Antacids, dairy, calcium-rich foods, mineral supplements: bind eltrombopag and reduce absorption.
  • Statins (such as rosuvastatin) and other OATP1B1/BCRP drugs: levels may rise, so doses may need reducing.
  • Interferon plus ribavirin: raises liver decompensation risk in hepatitis C.
  • Lab tests: eltrombopag is highly colored and can interfere with results.

Interactions listed in the FDA-approved label

From the Eltrombopag prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Polyvalent cations (iron, calcium, aluminum, magnesium, selenium, zinc) in antacids, dairy products, mineral supplements: Eltrombopag chelates polyvalent cations, significantly reducing its absorption. Take eltrombopag tablets at least 2 hours before or 4 hours after any medications or products containing polyvalent cations.
  • OATP1B1 substrates (e.g., atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, olmesartan, pitavastatin, pravastatin, rosuvastatin, repaglinide, rifampin, simvastatin acid, SN-38, valsartan): Eltrombopag may cause excessive exposure to substrates of OATP1B1. Use caution; monitor closely for signs and symptoms of excessive exposure and consider reducing the dose of these drugs if appropriate. In clinical trials a rosuvastatin dose reduction by 50% was recommended.
  • BCRP substrates (e.g., imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, rosuvastatin, sulfasalazine, topotecan): Eltrombopag may cause excessive exposure to substrates of BCRP. Use caution; monitor closely for signs and symptoms of excessive exposure and consider reducing the dose of these drugs if appropriate.
  • HIV protease inhibitors (lopinavir/ritonavir): No dose adjustment is recommended when coadministered with lopinavir/ritonavir; interactions with other HIV protease inhibitors have not been evaluated. No dose adjustment is recommended.
  • Hepatitis C virus protease inhibitors (boceprevir, telaprevir): No dose adjustments are recommended when coadministered with boceprevir or telaprevir; interactions with other HCV protease inhibitors have not been evaluated. No dose adjustments are recommended.
  • Peginterferon alfa-2a or -2b: No dose adjustments are recommended when coadministered with peginterferon alfa-2a or -2b. No dose adjustments are recommended.
  • Clinical laboratory tests (bilirubin and creatinine): Eltrombopag is highly colored and can cause sample discoloration, interfering with bilirubin assays (positive and negative) and creatinine measurements (falsely elevated). If results are inconsistent with clinical observations or unexpected, evaluate liver or renal function further, communicate to the lab that the patient takes eltrombopag, and consider re-testing using other methods.
Read the label’s full interactions text

7 DRUG INTERACTIONS 7.1 Polyvalent Cations (Chelation) Eltrombopag chelates polyvalent cations (such as iron, calcium, aluminum, magnesium, selenium, and zinc) in foods, mineral supplements, and antacids. Take eltrombopag tablets at least 2 hours before or 4 hours after any medications or products containing polyvalent cations, such as antacids, dairy products, and mineral supplements to avoid significant reduction in absorption of eltrombopag tablets due to chelation [see Dosage and Administration (2.4), Clinical Pharmacology (12.3)] . 7.2 Transporters Use caution when concomitantly administering eltrombopag tablets and drugs that are substrates of OATP1B1 (e.g., atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, olmesartan, pitavastatin, pravastatin, rosuvastatin, repaglinide, rifampin, simvastatin acid, SN-38 [active metabolite of irinotecan], valsartan) or breast cancer resistance protein (BCRP) (e.g., imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, rosuvastatin, sulfasalazine, topotecan). Monitor patients closely for signs and symptoms of excessive exposure to the drugs that are substrates of OATP1B1 or BCRP and consider reduction of the dose of these drugs, if appropriate. In clinical trials with eltrombopag tablets, a dose reduction of rosuvastatin by 50% was recommended. 7.3 Protease Inhibitors HIV Protease Inhibitors: No dose adjustment is recommended when eltrombopag tablets are coadministered with lopinavir/ritonavir (LPV/RTV). Drug interactions with other HIV protease inhibitors have not been evaluated. Hepatitis C Virus Protease Inhibitors: No dose adjustments are recommended when eltrombopag tablets are coadministered with boceprevir or telaprevir. Drug interactions with other hepatitis C virus (HCV) protease inhibitors have not been evaluated. 7.4 Peginterferon Alfa-2a/b Therapy No dose adjustments are recommended when eltrombopag tablets are coadministered with peginterferon alfa-2a (PEGASYS ® ) or -2b (PEGINTRON ® ).

Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

🌿55 supplements and herbs with documented Eltrombopag interactions, ranked by severity Check Eltrombopag against a supplement or herb →

Before taking Eltrombopag

▾
  • Tell your prescriber about liver disease, hepatitis C, clotting risks, or MDS.
  • Get an eye exam before starting.
  • Pregnancy: can cause fetal harm; use effective contraception during treatment and for at least 7 days after.
  • Breastfeeding is not recommended.
  • Children: approved ages differ by product and condition.
  • Older adults: no overall differences in safety or effectiveness were seen.
  • Lower starting amounts may be needed with liver impairment or East-/Southeast-Asian ancestry for some conditions.

Eltrombopag overdose

▾

Too much can push platelet counts very high and cause blood clots. One reported large overdose led to a platelet count of 929 and also caused rash, slow heartbeat, liver test elevations, and fatigue. The label suggests taking a calcium-, aluminum-, or magnesium-containing product to limit absorption and closely monitoring platelets. Call Poison Help at 1-800-222-1222.

What Eltrombopag does in the body

▾

Eltrombopag raises platelet counts in a dose-dependent way with daily dosing. Counts peak about two weeks after starting and return to baseline about two weeks after the last dose. At doses up to the maximum recommended, it did not meaningfully affect the heart's QT interval.

How your body processes Eltrombopag

▾

Eltrombopag peaks 2 to 6 hours after a dose. A high-calcium meal sharply lowers absorption, which is why timing matters. It is heavily metabolized, mostly cleared in feces, and has a half-life of roughly 21 to 35 hours. Levels are higher in liver impairment and in people of East-/Southeast-Asian ancestry, and the oral suspension delivered about 22% more exposure than the tablet.

How to store Eltrombopag

▾

Store at room temperature between 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) . Dispense in original bottle.

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

55

Supplements & herbs that interact with Eltrombopag

55 supplements and herbal products have documented interactions with Eltrombopag in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.

Severity mix
  • Major · 4
  • Moderate · 42
  • Minor · 9
ACTIVATED CHARCOAL Major BEER Major SIBERIAN COCKLEBUR Major WINE Major ASHWAGANDHA Moderate BLACK COHOSH Moderate BOLDO Moderate BUCHU Moderate +47 more
Every supplement checked against Eltrombopag — ranked by severity The full interaction hub: 4 major · 42 moderate · 9 minor · every one linked to its full report. Check Eltrombopag against your exact supplements

Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.

Eltrombopag: pharmacist answers to common questions

Quick, plain-English answers to the questions patients ask most about Eltrombopag — the kind of thing our pharmacy team would talk through with you at the counter.

What is eltrombopag for?

▾
It raises low platelet counts in persistent or chronic ITP and in chronic hepatitis C, so hepatitis C treatment with interferon can proceed. It also treats severe aplastic anemia. Which of these applies depends on the product and your age.

How should I take it?

▾
Take it by mouth, usually once a day, on an empty stomach or with a low-calcium meal. Keep it 2 hours before or 4 hours after antacids, dairy, and mineral supplements. Follow your prescriber's directions on amount.

Why does it matter what I eat?

▾
Calcium and other minerals bind eltrombopag and keep your body from absorbing it. A high-calcium meal cut absorption a lot in studies. Spacing them out keeps the medicine working.

What side effects should I expect?

▾
Common ones include nausea, diarrhea, headache, tiredness, fever, and cough. Liver blood tests can also rise, which is why they are checked often.

When should I call my doctor?

▾
Call right away for yellow skin or eyes, dark urine, belly swelling or pain, confusion, signs of a blood clot, vision changes, or unusual bleeding. These can mean liver problems or clots.

Is it safe in pregnancy?

▾
Animal studies show it can harm a fetus. If you can become pregnant, use effective contraception during treatment and for at least 7 days after. Breastfeeding is not recommended.

Is Eltrombopag available over the counter?

▾
No. Eltrombopag is a prescription medicine: every Eltrombopag product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was Eltrombopag first available?

▾
The earliest FDA record we hold for Eltrombopag is from 2008: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when Eltrombopag was first used.

Who makes Eltrombopag?

▾
14 companies currently list Eltrombopag products in the FDA's NDC Directory, including Amneal Pharmaceuticals NY LLC, Teva Pharmaceuticals, Inc., Camber Pharmaceuticals, Inc.. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →

More about Eltrombopag on HelloPharmacist

📊Eltrombopag supplement interactions55 checked — ranked by severity 🌿Drug & Supplement CheckerEltrombopag vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Eltrombopag NDCs & costs 🅰️Browse Drugs A–ZLook up any medication
Detailed data & references for Eltrombopag Forms & strengths, pricing, billing codes, manufacturers, safety reports and sourcing — the data behind the page. Most people can stop here. Each section below opens on a tap.

Eltrombopag forms and strengths (how it comes)

Eltrombopag is available in 2 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Eltrombopag inactive ingredients by manufacturer.

Tablet

By mouth
Brands Alvaiz Eltrombopag Olamine Promacta
How this form is used
What it may be used for
  • Eltrombopag tablets are used for ITP in patients 1 year and older, hepatitis C-related low platelets, and severe aplastic anemia including first-line use with immunosuppressive therapy.
  • Alvaiz is used for ITP in patients 6 years and older, for chronic hepatitis C thrombocytopenia in adults, and for adults with severe aplastic anemia that did not respond enough to immunosuppressive therapy.
Important instructions
  • Eltrombopag tablets are taken without a meal or with a meal low in calcium.
  • Eltrombopag tablets are taken at least 2 hours before or 4 hours after antacids, calcium-rich foods, and mineral supplements.
  • Alvaiz is not substitutable with other eltrombopag products on a milligram-for-milligram basis.
Available strengths 8 strengths
9 mg 12.5 mg 18 mg 25 mg 36 mg 50 mg
Show 2 more strengths Show fewer strengths
54 mg 75 mg
94 FDA-listed product records ⓘ

Oral suspension

By mouth
Brands Promacta
How this form is used
What it may be used for
  • Eltrombopag for oral suspension is used for thrombocytopenia in persistent or chronic ITP in patients 1 year and older.
  • Eltrombopag for oral suspension is used for thrombocytopenia in chronic hepatitis C so interferon-based therapy can start and continue.
  • Eltrombopag for oral suspension is used for severe aplastic anemia that did not respond enough to immunosuppressive therapy.
Important instructions
  • Eltrombopag for oral suspension is taken without a meal or with a meal low in calcium.
  • Eltrombopag for oral suspension is taken at least 2 hours before or 4 hours after antacids, calcium-rich foods, and mineral supplements.
Available strengths 2 strengths
12.5 mg 25 mg
8 FDA-listed product records ⓘ

Eltrombopag on the U.S. market: products, makers and brands

How Eltrombopag appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

14 companies list 68 Eltrombopag product records with the FDA, mostly as tablet, oral suspension; the earliest marketing or approval year on record is 2008. Brand names on the directory include Promacta, Alvaiz, Eltrombopag Olamine; the rest are generics.

2
Dose forms ⓘ
14
Labelers (makers, repackagers, distributors)
4
Brand names
68
FDA-listed product records ⓘ
2008
Earliest FDA record ⓘ

FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

Also listed with the FDA, not a patient dose form: Powder (23) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

Amneal Pharmaceuticals NY LLC12%
Teva Pharmaceuticals, Inc.12%
Camber Pharmaceuticals, Inc.9%
Novartis Pharmaceuticals Corporation9%
Amerisyn, LLC6%
AvKARE6%
Other makers47%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How widely Eltrombopag is used (Medicaid data)

A general measure of how commonly Eltrombopag is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Eltrombopag is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

11,114
Medicaid prescriptions filled (Q1–Q4 2025)
$166.4M gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Eltrombopag prescribed? Of the 1,601 medications we measure, Eltrombopag ranks #914 by Medicaid prescriptions — more than 43% of them.

Where Eltrombopag ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #914 of 1,601
#909 Insulin Detemir (rDNA... 11,349 Rx #910 Chlorothiazide 11,327 Rx #911 Magnesium Chloride / P... 11,275 Rx #912 Deferasirox 11,233 Rx #913 Tavaborole Topical 11,126 Rx #914 Eltrombopag 11,114 Rx #915 Palbociclib 11,110 Rx #916 Rivastigmine 11,022 Rx #917 Drospirenone / Ethinyl... 10,895 Rx #918 Dronedarone 10,844 Rx #919 Pyrethrin and Piperony... 10,703 Rx

Utilization by Eltrombopag product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

The 50 mg oral tablet is the most-dispensed Eltrombopag product — about 42% of these Medicaid prescriptions.

eltrombopag 50 MG Oral Tablet Most dispensed

4,697 Medicaid prescriptions (Q1–Q4 2025) 42% of Eltrombopag prescriptions shown $67.5M gross reimbursement (before rebates) ≈ $14,362 per prescription (gross)

Summed across the 2 of 21 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 825427

eltrombopag 25 MG Oral Tablet

3,090 Medicaid prescriptions (Q1–Q4 2025) 28% of Eltrombopag prescriptions shown $29.5M gross reimbursement (before rebates) ≈ $9,555 per prescription (gross)

Summed across the 2 of 12 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 825421

eltrombopag 75 MG Oral Tablet

2,339 Medicaid prescriptions (Q1–Q4 2025) 21% of Eltrombopag prescriptions shown $57.4M gross reimbursement (before rebates) ≈ $24,523 per prescription (gross)

Summed across the 2 of 14 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 884617

eltrombopag 25 MG Powder for Oral Suspension

376 Medicaid prescriptions (Q1–Q4 2025) 3% of Eltrombopag prescriptions shown $5.3M gross reimbursement (before rebates) ≈ $14,107 per prescription (gross)

Summed across the 2 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1859498

eltrombopag 12.5 MG Oral Tablet

368 Medicaid prescriptions (Q1–Q4 2025) 3% of Eltrombopag prescriptions shown $3.4M gross reimbursement (before rebates) ≈ $9,165 per prescription (gross)

Summed across the 2 of 12 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1245001

eltrombopag 18 MG Oral Tablet

82 Medicaid prescriptions (Q1–Q4 2025) <1% of Eltrombopag prescriptions shown $641,751 gross reimbursement (before rebates) ≈ $7,826 per prescription (gross)

Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2675187

eltrombopag 36 MG Oral Tablet

77 Medicaid prescriptions (Q1–Q4 2025) <1% of Eltrombopag prescriptions shown $1.2M gross reimbursement (before rebates) ≈ $15,428 per prescription (gross)

Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2675195

eltrombopag 54 MG Oral Tablet

51 Medicaid prescriptions (Q1–Q4 2025) <1% of Eltrombopag prescriptions shown $1.1M gross reimbursement (before rebates) ≈ $20,992 per prescription (gross)

Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2675199

eltrombopag 12.5 MG Powder for Oral Suspension

34 Medicaid prescriptions (Q1–Q4 2025) <1% of Eltrombopag prescriptions shown $488,916 gross reimbursement (before rebates) ≈ $14,380 per prescription (gross)

Summed across the 2 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2058980

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Eltrombopag, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 15 of 74 listed Eltrombopag NDCs with Medicaid activity.

Compare Eltrombopag products

A representative set of FDA-listed product records for Eltrombopag — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 68 of 68 products — FDA National Drug Code Directory. See every product, package size and price: browse all 68 Eltrombopag NDCs →

Eltrombopag recall history

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Eltrombopag recalls since July 2021.

✅No Eltrombopag recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Eltrombopag RxCUI 711942 2 dose forms · 10 strengths
  1. Dose form (SCDF) Oral Tablet RxCUI 825420 In current FDA listings
    Clinical drug / strength (SCD) 9 MG RxCUI 2675203 12.5 MG RxCUI 1245001 18 MG RxCUI 2675187 25 MG RxCUI 825421 36 MG RxCUI 2675195 50 MG RxCUI 825427 54 MG RxCUI 2675199 75 MG RxCUI 884617
  2. Dose form (SCDF) Powder for Oral Suspension RxCUI 1665882 In current FDA listings
    Clinical drug / strength (SCD) 12.5 MG RxCUI 2058980 25 MG RxCUI 1859498

Look up RxCUI 711942 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

💵 What Eltrombopag costs pharmacies (NADAC benchmark)

The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.

FormStrengthPharmacy acquisition benchmark
Tablet · Oral 50 mg $25.85 per tablet NDC details & price history
Why show this? Your out-of-pocket cost depends on insurance, pharmacy markup, and discounts — but the acquisition benchmark tells you whether the medication itself is inexpensive or costly, which strengths cost more per dose, and whether a cash-price quote is in a reasonable range. Each row links to the NDC-level record with its full price history.

Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.

Eltrombopag brand names

Eltrombopag is sold under 3 brand names in the FDA directory — Promacta, Alvaiz, Eltrombopag Olamine. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.

Promacta Alvaiz Eltrombopag Olamine

Who makes Eltrombopag: manufacturers and labelers

14 companies list Eltrombopag products with the FDA. By number of product records, the largest are Amneal Pharmaceuticals NY LLC, Teva Pharmaceuticals, Inc., Camber Pharmaceuticals, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Amneal Pharmaceuticals NY LLC 8 Teva Pharmaceuticals, Inc. 8 Camber Pharmaceuticals, Inc. 6 Novartis Pharmaceuticals Corporation 6 Amerisyn, LLC 4 AvKARE 4 Biocon Pharma Inc. 4 Dr. Reddy's Laboratories Inc., 4 Hikma Pharmaceuticals USA Inc. 4 Novadoz Pharmaceuticals LLC 4 Somerset Therapeutics, LLC 4 XLCare Pharmaceuticals Inc. 4 Zydus Lifesciences Limited 4 Zydus Pharmaceuticals USA Inc. 4

Eltrombopag drug class (RxNorm)

Eltrombopag belongs to the Thrombopoietin Receptor Agonist class.

Pharmacologic class Thrombopoietin Receptor Agonist
Drug family (ATC) Other systemic hemostatics
How it works Thrombopoietin Receptor Agonists, Organic Anion Transporting Polypeptide 1B1 Inhibitors, Breast Cancer Resistance Protein Inhibitors, UGT1A1 Inhibitors

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

Sources for this Eltrombopag page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Jan 30, 2026
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Eltrombopag.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Eltrombopag after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
16
Finished products in the current FDA directory
68
Companies listing them (makers, repackagers, distributors)
14
FDA labeler codes behind them ⓘ
15
Linked representative label ⓘ
Teva Pharmaceuticals, Inc.
Linked label effective
Jan 30, 2026
Composite sections available
24
Linked SPL Set ID
ed51e463-7a03-4858-bbd2-882ce4753d5a
Linked SPL Document ID
a573cf28-59db-4cb3-84db-af7b77200b66
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Teva Pharmaceuticals, Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →